SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy

He discusses the company's degrader programs, TYK2/JAK1, using myostatin for obesity, and a Kv7 epilepsy program that will have key data this year.

Episode metadata supplied by the publisher feed · Published Jan 12, 2026

Embed this episode

Attribution link and audio player

Ready to play

SF Healthcare Week: Biohaven's Chairman & CEO Vlad Coric shares updates on the company's pipeline in immunology, obesity, and epilepsy

0:00 10:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 10 minutes long.

This episode was published on January 12, 2026.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!